NCT04337112Approved For Marketing不适用
The Expanded Access Use of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy (DMD) Amenable to Exon 53 Skipping
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is an open label expanded access program for boys, 3 to 12 years old, for the treatment of Duchenne muscular dystrophy (DMD) with confirmed mutation(s) in the dystrophin gene that is amenable to skipping of exon 53.
详细描述
This expanded access program is designed to provide access to viltolarsen in patients with DMD with confirmed mutation(s) in the dystrophin gene amenable to skipping of exon 53, who in the opinion and clinical judgement of the treating physician, would benefit from treatment with viltolarsen.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 3 Years 至 12 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male ≥ 3 and ≤ 12 years of age
- •Clinical signs compatible with DMD
- •Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 53 to restore the dystrophin messenger ribonucleic acid (mRNA) reading frame
- •Able to walk independently without assistive device
- •Not able to participate in a Phase 3 trial
排除标准
- •Chronic systemic fungal or viral infections
- •An acute illness within 4 weeks prior to the first dose of viltolarsen
- •Symptomatic cardiomyopathy
- •Patient has a previous or ongoing medical condition, medical history, physical findings, or laboratory abnormality that could affect participant safety in the opinion of the treating physician
- •Surgery within the 3 months prior to the first anticipated administration of viltolarsen and in the opinion of the treating physician would impact weekly treatment schedule
- •Positive test results for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) antibody at screening
- •Currently taking any other investigational drug or has taken any other investigational drug within 3 months prior to the first dose of viltolarsen
- •Previously enrollment in any viltolarsen study.
- •Currently taking any other exon skipping agent or has taken any other exon skipping agent within 2 weeks prior to the first dose of viltolarsen (would need to be discontinued in order to be eligible)
- •Any gene therapy for DMD
- •Inadequate renal function as defined by a serum cystatin C > 1.5 x upper limit of normal (ULN). If the value is > 1.5 x ULN then the measurement can be repeated once. If repeat measurement is still > 1.5 x ULN then the patient should be excluded.
研究者
相似试验
No Longer Available
不适用
Viaskin® Peanut (DBV712) Expanded Access ProtocolPeanut AllergyNCT04371627DBV Technologies
Approved For Marketing
不适用
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT02592941PTC Therapeutics
Available
不适用
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 DeficiencyMonocarboxylate Transporter 8 DeficiencyAllan-Herndon-Dudley SyndromeNCT05911399Rare Thyroid Therapeutics International AB
Temporarily Not Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
Available
不适用
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's DiseaseAlzheimer DiseaseNCT03539380TauRx Therapeutics Ltd